ISRG
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Intuitive Surgical, Inc.
- Nom
- Intuitive Surgical, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $159.9B
- Employés
- 17,021
- PDG
- David J. Rosa
- Site web
- https://www.intuitive.com
- Marché
- CNMDGNGBYMBOTOCPNFSMMNYSNN
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 1 150 titres (~510 370,00 $ US)
- Insiders
- BARRATT CRAIG H
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$766,715
Avg sell (VWAP, 90d window) $377.88 vs last close $451.63 (+19.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$766,715 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-23
- Liquidity
- Liquid $1,034,421,639/day · 20d vol
- Last synced
-
2026-10-26 22:35:44
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | Widman Fredrik | Sell · S · 10b5-1 | 543 | $374.44 | $203,321 | Form 4 |
| 2026-09-11 | Brosius Mark | Sell · S · 10b5-1 | 25 | $365.79 | $9,145 | Form 4 |
| 2026-09-10 | Brosius Mark | Sell · S · 10b5-1 | 23 | $347.66 | $7,996 | Form 4 |
| 2026-09-09 | Brosius Mark | Sell · S · 10b5-1 | 23 | $350.20 | $8,055 | Form 4 |
| 2026-09-08 | Brosius Mark | Sell · S · 10b5-1 | 46 | $361.23 | $16,617 | Form 4 |
| 2026-08-21 | Brosius Mark | Sell · S · 10b5-1 | 77 | $375.57 | $28,919 | Form 4 |
| 2026-08-20 | Brosius Mark | Sell · S · 10b5-1 | 77 | $396.37 | $30,520 | Form 4 |
| 2026-08-19 | Brosius Mark | Sell · S · 10b5-1 | 77 | $394.26 | $30,358 | Form 4 |
| 2026-08-18 | Brosius Mark | Sell · S · 10b5-1 | 77 | $394.00 | $30,338 | Form 4 |
| 2026-08-17 | Brosius Mark | Sell · S · 10b5-1 | 77 | $390.67 | $30,082 | Form 4 |
| 2026-08-11 | Ladd Amy L | Sell · S · 10b5-1 | 72 | $393.10 | $28,303 | Form 4 |
| 2026-08-10 | Ladd Amy L | Sell · S · 10b5-1 | 400 | $379.00 | $151,600 | Form 4 |
| 2026-08-10 | LOEB GARY | Sell · S · 10b5-1 | 400 | $379.00 | $151,600 | Form 4 |
| 2026-07-31 | Brosius Mark | Sell · S · 10b5-1 | 28 | $351.00 | $9,828 | Form 4 |
| 2026-07-30 | Brosius Mark | Sell · S · 10b5-1 | 28 | $346.83 | $9,711 | Form 4 |
| 2026-07-29 | Brosius Mark | Sell · S · 10b5-1 | 28 | $360.21 | $10,086 | Form 4 |
| 2026-07-28 | Brosius Mark | Sell · S · 10b5-1 | 28 | $365.58 | $10,236 | Form 4 |
| 2026-07-27 | Brosius Mark | Sell · S · 10b5-1 | 28 | $344.00 | $9,632 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-07 | Michael McCaul | Buy | $15,001 - $50,000 | Filing |
| 2026-09-25 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-11 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-09-04 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-09-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-09-04 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-08-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-08-07 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2026-05-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2025-12-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-03 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-16 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-10 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-09 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-08 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-07 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-04-07 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-01-29 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-01-10 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-23 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-07-22 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-07-17 | Greg Landsman | Sale (Full) | $15,001 - $50,000 |
| 2024-07-17 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2024-06-25 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-06-20 | Greg Landsman | Purchase | $15,001 - $50,000 |
| 2024-05-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-03-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-03-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-01-29 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-27 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-12 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-01 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-02 | Greg Landsman | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-28 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-07-20 | William R. Keating | Purchase | $1,001 - $15,000 |
| 2023-07-07 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Sale | $100,001 - $250,000 |
| 2023-06-26 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-05-30 | Greg Landsman | Purchase | $1,001 - $15,000 |
| 2023-05-30 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-05-04 | Greg Landsman | Purchase | $1,001 - $15,000 |
| 2023-05-01 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-02-01 | Greg Landsman | Purchase | $1,001 - $15,000 |
| 2023-01-31 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2022-12-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-10-12 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-12 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-08-15 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-07-25 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-28 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2022-06-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2022-06-10 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-04-20 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-11 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $15,001 - $50,000 |
| 2022-02-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $50,001 - $100,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-26 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-01-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-12-01 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-22 | John R. Curtis | Purchase | $1,001 - $15,000 |
| 2021-05-04 | Kathy E. Manning | Sale (Partial) | $1,001 - $15,000 |
| 2021-02-23 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-02-16 | Peter Meijer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-05 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-26 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
ISRG combines exceptional financial health (liquidity 95, fundamentals 85) with a moderate earnings catalyst (60), supported by rising EPS estimates and Strong Buy consensus, justifying a solid WATCH stance.
The first sentence of the analysis written for ISRG on 2026-10-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $776K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $776K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Unavailable or mixed. 7 purchase disclosures year to date, a thin reading
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 4.87 · operating margin 29%
Suggested stop 411.12, nearest stored support minus 0.5 ATR(9.0% under the last close). Reward/risk to the next stored resistance is 0.98. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Intuitive Surgical (ISRG) is an Incredible Growth Stock: 3 Reasons Why Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.
- 2026-10-26 Earnings Estimates Moving Higher for Intuitive Surgical (ISRG): Time to Buy? Intuitive Surgical, Inc. (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 2026-10-26 Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- 2026-10-24 Boomfish Wealth Group LLC Buys 2,900 Shares of Intuitive Surgical, Inc. $ISRG Boomfish Wealth Group LLC raised its position in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 112.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,469 shares of the medical equipment provider''s stock after acquiring an additional 2,900 shares during
- 2026-10-23 New Strong Buy Stocks for October 23rd UVE, HAS, TXN, URI and ISRG have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2026.
- 2026-10-23 Intuitive Surgical, Inc. $ISRG Shares Sold by Cadinha & Co. LLC Cadinha and Co. LLC decreased its stake in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 44.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,413 shares of the medical equipment provider''s stock after selling 22,531 shares during the
- 2026-10-22 Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought Ark Invest bought into some market laggards on Wednesday.
- 2026-10-22 Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story Intuitive Surgical NASDAQ: ISRG shocked the market by reporting not one but two margin impairments in its Q3 results, but investors shouldn''t misread this.
- 2026-10-22 Intuitive Surgical (NASDAQ:ISRG) Given “Buy” Rating at BTIG Research Intuitive Surgical (NASDAQ: ISRG - Get Free Report)''s stock had its "buy" rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $454.00 price target on the medical equipment provider''s stock. BTIG Research''s price target would suggest a potential upside of 6.05%
- 2026-10-21 2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 66.0% | 67.5% | 66.4% | 67.4% | 69.3% | |
| Ebit Margin | 32.9% | 32.0% | 27.5% | 25.8% | 33.1% | |
| Ebitda Margin | 39.6% | 37.5% | 33.9% | 31.7% | 38.5% | |
| Operating Profit Margin | 29.3% | 28.1% | 24.8% | 25.3% | 31.9% | |
| Pretax Profit Margin | 32.9% | 32.0% | 27.5% | 25.8% | 33.1% | |
| Continuous Operations Profit Margin | 28.6% | 28.0% | 25.5% | 21.6% | 30.3% | |
| Net Profit Margin | 28.4% | 27.8% | 25.2% | 21.3% | 29.9% | |
| Bottom Line Profit Margin | 28.4% | 27.8% | 25.2% | 21.3% | 29.9% | |
| Current Ratio | 4.875 | 4.074 | 4.756 | 4.397 | 5.083 | |
| Quick Ratio | 3.957 | 3.222 | 4.020 | 3.769 | 4.573 | |
| Solvency Ratio | 1.314 | 1.206 | 1.102 | 0.907 | 1.257 | |
| Cash Ratio | 1.679 | 1.162 | 1.658 | 1.112 | 1.123 | |
| Price To Earnings Ratio | 70.795 | 79.810 | 65.891 | 71.331 | 75.010 | |
| Price To Earnings Growth Ratio | 3.171 | 2.878 | 1.751 | -3.193 | 1.280 | |
| Forward Price To Earnings Growth Ratio | 3.171 | 2.878 | 1.751 | -3.193 | 1.280 | |
| Price To Earnings Diluted Ratio | 71.964 | 81.302 | 67.070 | 72.699 | 77.103 | |
| Price To Earnings Diluted Growth Ratio | 3.186 | 2.942 | 1.774 | -3.354 | 1.318 | |
| Price To Book Ratio | 11.341 | 11.282 | 8.903 | 8.548 | 10.705 | |
| Price To Sales Ratio | 20.083 | 22.198 | 16.631 | 15.169 | 22.407 | |
| Price To Free Cash Flow Ratio | 81.155 | 142.200 | 158.059 | 98.482 | 73.706 | |
| Price To Operating Cash Flow Ratio | 66.700 | 76.770 | 65.322 | 63.312 | 61.236 | |
| Debt To Assets Ratio | 0.015 | 0.008 | 0.000 | 0.000 | 0.006 | |
| Debt To Equity Ratio | 0.017 | 0.009 | 0.000 | 0.000 | 0.007 | |
| Debt To Capital Ratio | 0.017 | 0.009 | 0.000 | 0.000 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.007 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.157 | 1.146 | 1.160 | 1.175 | 1.134 | |
| Working Capital Turnover Ratio | 1.532 | 1.441 | 1.288 | 1.306 | 1.103 | |
| Operating Cash Flow Ratio | 1.511 | 1.384 | 1.094 | 1.048 | 1.817 | |
| Operating Cash Flow Sales Ratio | 0.301 | 0.289 | 0.255 | 0.240 | 0.366 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.822 | 0.540 | 0.413 | 0.643 | 0.831 | |
| Debt Service Coverage Ratio | 91.121 | 83.567 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 77.705 | 72.090 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 10.008 | 16.541 | 0.000 | 0.000 | 24.016 | |
| Capital Expenditure Coverage Ratio | 5.614 | 2.173 | 1.704 | 2.800 | 5.911 | |
| Dividend Paid And Capex Coverage Ratio | 5.614 | 2.173 | 1.704 | 2.800 | 5.911 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 49.911 | 58.524 | 47.947 | 47.046 | 57.597 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 66.0% | ▼-1.5% | ▼-1.3% |
| Ebit Margin | 32.9% | ▲0.9% | ▲2.6% |
| Ebitda Margin | 39.6% | ▲2.1% | ▲3.4% |
| Operating Profit Margin | 29.3% | ▲1.1% | ▲1.4% |
| Pretax Profit Margin | 32.9% | ▲0.9% | ▲2.6% |
| Continuous Operations Profit Margin | 28.6% | ▲0.6% | ▲1.8% |
| Net Profit Margin | 28.4% | ▲0.6% | ▲1.9% |
| Bottom Line Profit Margin | 28.4% | ▲0.6% | ▲1.9% |
| Current Ratio | 4.875 | ▲0.800 | ▲0.238 |
| Quick Ratio | 3.958 | ▲0.735 | ▲0.049 |
| Solvency Ratio | 1.314 | ▲0.108 | ▲0.157 |
| Cash Ratio | 1.679 | ▲0.517 | ▲0.332 |
| Price To Earnings Ratio | 70.795 | ▼-9.015 | ▼-1.772 |
| Price To Earnings Growth Ratio | 3.171 | ▲0.294 | ▲1.994 |
| Forward Price To Earnings Growth Ratio | 3.171 | ▲0.294 | ▲1.994 |
| Price To Earnings Diluted Ratio | 71.964 | ▼-9.338 | ▼-2.063 |
| Price To Earnings Diluted Growth Ratio | 3.186 | ▲0.244 | ▲2.013 |
| Price To Book Ratio | 11.341 | ▲0.059 | ▲1.185 |
| Price To Sales Ratio | 20.083 | ▼-2.115 | ▲0.786 |
| Price To Free Cash Flow Ratio | 81.156 | ▼-61.044 | ▼-29.565 |
| Price To Operating Cash Flow Ratio | 66.700 | ▼-10.070 | ▲0.032 |
| Debt To Assets Ratio | 0.015 | ▲0.007 | ▲0.009 |
| Debt To Equity Ratio | 0.017 | ▲0.008 | ▲0.010 |
| Debt To Capital Ratio | 0.017 | ▲0.008 | ▲0.010 |
| Long Term Debt To Capital Ratio | 0.007 | ▲0.007 | ▲0.006 |
| Financial Leverage Ratio | 1.157 | ▲0.011 | ▲0.003 |
| Working Capital Turnover Ratio | 1.532 | ▲0.091 | ▲0.198 |
| Operating Cash Flow Ratio | 1.511 | ▲0.127 | ▲0.140 |
| Operating Cash Flow Sales Ratio | 0.301 | ▲0.012 | ▲0.011 |
| Free Cash Flow Operating Cash Flow Ratio | 0.822 | ▲0.282 | ▲0.172 |
| Debt Service Coverage Ratio | 91.121 | ▲7.553 | ▲56.183 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 77.705 | ▲5.616 | ▲47.746 |
| Operating Cash Flow Coverage Ratio | 10.008 | ▼-6.533 | ▼-0.105 |
| Capital Expenditure Coverage Ratio | 5.614 | ▲3.441 | ▲1.974 |
| Dividend Paid And Capex Coverage Ratio | 5.614 | ▲3.441 | ▲1.974 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 49.911 | ▼-8.613 | ▼-2.295 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $202.13B | $185.40B | $118.48B | $94.38B | $127.95B | |
| Enterprise value | $199.07B | $183.52B | $115.73B | $92.80B | $126.74B | |
| EV / Sales | 19.78x | 21.97x | 16.25x | 14.91x | 22.20x | |
| EV / Op. cash flow | 65.69x | 75.99x | 63.81x | 62.25x | 60.66x | |
| EV / Free cash flow | 79.92x | 140.76x | 154.39x | 96.83x | 73.01x | |
| EV / EBITDA | 49.91x | 58.52x | 47.95x | 47.05x | 57.60x | |
| Net debt / EBITDA | -0.77x | -0.60x | -1.14x | -0.80x | -0.55x | |
| Current ratio | 4.88x | 4.07x | 4.76x | 4.40x | 5.08x | |
| Income quality | 1.05x | 1.03x | 1.00x | 1.11x | 1.21x | |
| Graham number | $95 | $83 | $66 | $51 | $60 | |
| Graham net-net | $15 | $10 | $13 | $10 | $10 | |
| Tax burden | 86.2% | 86.9% | 91.8% | 82.3% | 90.2% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $7.77B | $5.37B | $6.23B | $4.83B | $4.70B | |
| Invested capital | $13.50B | $10.52B | $10.15B | $7.60B | $6.99B | |
| Return on assets | 13.8% | 12.3% | 11.6% | 10.2% | 12.6% | |
| Operating ROA | 14.9% | 13.7% | 12.4% | 11.9% | 14.7% | |
| Return on tangible assets | 14.1% | 12.6% | 11.9% | 10.5% | 13.0% | |
| Return on equity | 16.0% | 14.1% | 13.5% | 12.0% | 14.3% | |
| Return on invested capital | 13.7% | 12.0% | 11.9% | 11.4% | 13.4% | |
| Return on capital employed | 15.8% | 13.7% | 12.8% | 13.7% | 14.7% | |
| Earnings yield | 1.4% | 1.3% | 1.5% | 1.4% | 1.3% | |
| Free cash flow yield | 1.2% | 0.7% | 0.6% | 1.0% | 1.4% | |
| Capex / Op. cash flow | 17.8% | 46.0% | 58.7% | 35.7% | 16.9% | |
| Capex / Depreciation | 79.7% | 240.5% | 234.0% | 145.5% | 114.0% | |
| Capex / Sales | 5.4% | 13.3% | 14.9% | 8.6% | 6.2% | |
| SG&A / Sales | 23.7% | 25.6% | 27.6% | 28.0% | 25.7% | |
| R&D / Sales | 13.0% | 13.7% | 14.0% | 14.1% | 11.8% | |
| Stock comp / Sales | 7.8% | 8.1% | 8.4% | 8.2% | 7.9% | |
| Intangibles / Total assets | 1.8% | 2.0% | 2.5% | 3.1% | 3.1% | |
| Days sales outstanding | 59d | 59d | 65d | 63d | 57d | |
| Days payables outstanding | 27d | 26d | 29d | 26d | 25d | |
| Operating cycle | 255d | 259d | 251d | 224d | 179d | |
| Cash conversion cycle | 228d | 233d | 222d | 197d | 154d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+9.0%EV / Sales ▼-10.0%EV / EBITDA ▼-14.7%EV / Op. cash flow ▼-10.303Earnings yield ▲+0.002Graham number ▲+12.322
Profitability
Return on equity ▲+0.019Return on assets ▲+0.015Return on invested capital ▲+0.017Return on capital employed ▲+0.021Operating ROA ▲+0.012Income quality ▲+0.020Tax burden ▼-0.006
Efficiency
Days sales outstanding ▼-0.247Days payables outstanding ▲+1.234Operating cycle ▼-3.734Cash conversion cycle ▼-4.968Capex / Sales ▼-0.079R&D / Sales ▼-0.007
Balance-sheet strength
Current ratio ▲+0.800Net debt / EBITDA ▼-0.169Working capital ▲+2407600000.000Invested capital ▲+2977900000.000Intangibles / Total assets ▼-0.001
Change over 5 years
Valuation
Market cap ▲+58.0%EV / Sales ▼-10.9%EV / EBITDA ▼-13.3%EV / Op. cash flow ▲+5.028Earnings yield ▲+0.001Graham number ▲+34.703
Profitability
Return on equity ▲+0.018Return on assets ▲+0.013Return on invested capital ▲+0.003Return on capital employed ▲+0.011Operating ROA ▲+0.002Income quality ▼-0.156Tax burden ▼-0.039
Efficiency
Days sales outstanding ▲+1.965Days payables outstanding ▲+1.951Operating cycle ▲+75.861Cash conversion cycle ▲+73.910Capex / Sales ▼-0.008R&D / Sales ▲+0.013
Balance-sheet strength
Current ratio ▼-0.209Net debt / EBITDA ▼-0.221Working capital ▲+3078200000.000Invested capital ▲+6511500000.000Intangibles / Total assets ▼-0.012